Another vaccine manufacturer on the case

  • Novavax (NVAX) has already initiated development of a new recombinant spike protein based on the known genetic sequence of the new variant.
  • They believe that their vaccine is likely to provide protection against the new variant
  • will have new recombinant spike proton based on known genetic sequence of new variant ready for testing & manufacturing within the next few weeks

JnJ, AstraZeneca already on the case. Now Novavax joins the fight.